


Healthcare Industry News: HIV/AIDS
News Release - August 5, 2008
ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts Through 96 Weeks in Treatment-Naive HIV-Infected Patients When Taken With Other Anti-HIV Medicines
Source: Merck
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
